ArticleOncology letters2025
Managing severe dermatitis and grade 4 pneumonitis in a patient with non-small-cell lung cancer following pembrolizumab treatment: A case report.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inhibitors of the programmed death receptor 1 (PD-1) or its ligand PD-L1 are widely used in cancer treatment. Despite their efficacy, these immunotherapies can induce adverse effects, particularly dermatitis and pneumonitis. However, the prognosis of these conditions is infrequently reported. The present study discusses a case of a patient with non-small-cell lung cancer (NSCLC) who developed severe dermatitis and grade 4 pneumonitis following treatment with pembrolizumab. Initially, the patient was administered methylprednisolone at a dosage of 4 mg/kg/day. Reducing the dosage to 1 mg/kg/day exacerbated the pneumonitis, following which the patient was administered mycophenolate mofetil (MMF), which notably ameliorated both conditions. The methylprednisolone dosage was then gradually reduced to 4 mg daily. The present case represents a rare instance of simultaneous severe dermatitis and grade 4 pneumonitis in a patient with NSCLC following immunotherapy. The conditions were successfully managed with a combination of MMF with methylprednisolone, resolving the steroid-dependent dermatitis and pneumonitis. The patient maintained a partial remission, with a tumor size of >30% smaller compared with the initial tumor size, for >3 years following the cessation of immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.